metastatic breast cancer: BOLERO2, CLEOPATRA, SWOG S0226

As planned, Living Beyond Breast Cancer (LBBC) presented a teleconference today with Dr. Virginia F. Borges, who reviewed highlights of the San Antonio Breast Cancer Symposium (SABCS) 2011 in January. This presentation will be available at the LBBC site as a podcast; I will post the link here also when it becomes available.

In the meantime, here are three highlights that address treatment for metastatic breast cancer. The focus on these is the combination of treatments for better results in achieving longer periods of progression free survival (PFS) and overall survival. Some studies do not yet report overall survival, though all three clearly show improved results for PFS.


  • Phase III randomized trial comparing exemestane alone with exemestane plus everolimus
  • Lead investigator: Gabriel Hortobagyi, M.D.
  • four months delay in progression with combination
  • everolimus is an mTOR inhibitor
  • this treatment is for metastatic breast cancer ER positive

SWOG S0226

  • Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.
  • Study Coordinator(s): Rita S. Mehta, M.D., Kathy Albain, M.D.
  • six months additional time before progression with combination
  • this treatment is for metastatic breast cancer ER positive


  • Phase III randomized study comparing pertuzumab plus  trastuzumab (Herceptin) plus docetaxel chemotherapy with trastuzumab plus docetaxel for previously untreated patients
  • Lead investigator: José Baselga, M.D.
  • six months improvement to progression with combination of three drugs
  • this treatment is for metastatic breast cancer HER2neu positive

5 6 7 8
© 2004–2012 Donna Peach. All rights reserved.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s